Co-Authors
This is a "connection" page, showing publications co-authored by Alessandro Cozzi-Lepri and Cristina Mussini.
Connection Strength
2.800
-
Re: 'Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness' by Wolkewitz et al. Clin Microbiol Infect. 2021 07; 27(7):1043-1044.
Score: 0.944
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.233
-
Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator. Clin Microbiol Infect. 2021 Aug; 27(8):1137-1144.
Score: 0.231
-
Tocilizumab in COVID-19: finding the optimal route and dose - Authors' reply. Lancet Rheumatol. 2020 Dec; 2(12):e739-e740.
Score: 0.226
-
Tocilizumab for severe COVID-19 pneumonia - Authors' reply. Lancet Rheumatol. 2020 Nov; 2(11):e660-e661.
Score: 0.224
-
Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug; 2(8):e474-e484.
Score: 0.222
-
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
Score: 0.192
-
Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):417-422.
Score: 0.186
-
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar; 2(3):e98-106.
Score: 0.153
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.053
-
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
Score: 0.047
-
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
Score: 0.045
-
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
Score: 0.044